Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Alsina

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Narrative Inquiry in Bioethics|April 30, 2019
Malleable Transplant Criteria: At What Cost?Angel Alsina, Rebekah Apple, Nyingi Kemmer, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 30, 2013
Update on the management of cirrhosis - focus on cost-effective preventative strategiesGuy W Neff, Nyingi Kemmer, Christopher Duncan, et al.
The American Surgeon|August 2, 2018
Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psychosocial and Long-Term Outcome StudyAngel Alsina, Alexa Alsina, Alexia Athienitis, et al.
Transplantation|November 20, 2013
Nonalcoholic fatty liver disease epidemic and its implications for liver transplantationNyingi Kemmer, Guy W Neff, Edson Franco, et al.
Puerto Rico Health Sciences Journal|January 6, 2005
Improving access to liver transplantation: the University of Puerto Rico experienceEsther A Torres, Aileen Guzmán, María Vázquez, et al.
Archivos Espanoles De Urologia|August 16, 2003
[Genital histoplasmosis. Presentation of a clinical case]Norberto Rodríguez, Marcelo Sandoval, Angel Alsina, et al.
American Journal of Surgery|September 28, 2011
Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts?Whalen Clark, Farhaad Golkar, Kenneth Luberice, et al.
Viruses|October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated CirrhosisSteven Flamm, Eric Lawitz, Brian Borg, et al.
Liver Cancer|February 20, 2020
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular CarcinomaAngel Alsina, Masatoshi Kudo, Arndt Vogel, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Narrative Inquiry in Bioethics|April 30, 2019
Malleable Transplant Criteria: At What Cost?Angel Alsina, Rebekah Apple, Nyingi Kemmer, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 30, 2013
Update on the management of cirrhosis - focus on cost-effective preventative strategiesGuy W Neff, Nyingi Kemmer, Christopher Duncan, et al.
The American Surgeon|August 2, 2018
Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psychosocial and Long-Term Outcome StudyAngel Alsina, Alexa Alsina, Alexia Athienitis, et al.
Transplantation|November 20, 2013
Nonalcoholic fatty liver disease epidemic and its implications for liver transplantationNyingi Kemmer, Guy W Neff, Edson Franco, et al.
Puerto Rico Health Sciences Journal|January 6, 2005
Improving access to liver transplantation: the University of Puerto Rico experienceEsther A Torres, Aileen Guzmán, María Vázquez, et al.
Archivos Espanoles De Urologia|August 16, 2003
[Genital histoplasmosis. Presentation of a clinical case]Norberto Rodríguez, Marcelo Sandoval, Angel Alsina, et al.
American Journal of Surgery|September 28, 2011
Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts?Whalen Clark, Farhaad Golkar, Kenneth Luberice, et al.
Viruses|October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated CirrhosisSteven Flamm, Eric Lawitz, Brian Borg, et al.
Liver Cancer|February 20, 2020
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular CarcinomaAngel Alsina, Masatoshi Kudo, Arndt Vogel, et al.
Pageof 1